<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of the patient with COPD and cardiovascular disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of the patient with COPD and cardiovascular disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of the patient with COPD and cardiovascular disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Imre Noth, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory A Schmidt, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James K Stoller, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), which includes coronary heart disease, peripheral artery disease, and cerebrovascular disease, share tobacco abuse as a major risk factor. Thus, these two disorders commonly coexist. In addition, CVD is a leading cause of death among patients with COPD.</p><p>The management of patients with concurrent COPD and CVD will be reviewed here. The diagnosis and management of COPD and coronary heart disease occurring independently are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a> and  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a> and  <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a> and  <a class="medical medical_review" href="/z/d/html/1519.html" rel="external">"Screening for coronary heart disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">COPD/CVD RELATIONSHIP</span><span class="headingEndMark"> — </span>COPD and CVD frequently coexist, and the presence of one can affect outcomes in the other [<a href="#rid1">1</a>]. As symptoms can overlap, differentiating the relative contributions of these diseases to a given patient’s symptoms can be challenging.</p><p class="headingAnchor" id="H104140482"><span class="h2">Coexistence of COPD and CVD</span><span class="headingEndMark"> — </span>The frequent coexistence of COPD and CVD has been observed in several studies [<a href="#rid2">2-5</a>]. As an example, a study from a large United Kingdom database of more than 1.2 million patients over age 35 identified almost 30,000 patients with COPD; these patients were nearly five times more likely to have cardiovascular disease than those without COPD [<a href="#rid2">2</a>]. In a separate study of 351 patients with advanced COPD, clinically significant coronary disease was identified by angiography in 60 percent and was occult in 53 percent [<a href="#rid3">3</a>]. In a meta-analysis, patients with COPD were more likely to be diagnosed with cardiovascular disease (OR 2.46; 95% CI 2.02-3.00) than patients without COPD [<a href="#rid6">6</a>]. The cardiovascular diseases included ischemic heart disease, cardiac dysrhythmia, heart failure, diseases of the pulmonary circulation, and diseases of the systemic arteries.</p><p class="headingAnchor" id="H104140467"><span class="h2">Impact of comorbid disease on outcomes</span><span class="headingEndMark"> — </span>A large number of observational studies have found that the coexistence of COPD and cardiovascular disease has an important impact on clinical outcomes.</p><p>Cardiovascular morbidity and mortality in patients with COPD [<a href="#rid7">7-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with COPD may have independently increased risk for cardiovascular disease and mortality beyond known cardiovascular disease risk factors.</p><p></p><p class="bulletIndent1">In a large population-based cohort study of 5.8 million individuals age ≥40 years without known CVD, of whom approximately 150,000 had a diagnosis of COPD, rates of acute MI, stroke, or cardiovascular death over the following eight years were 3.3 times higher in patients with compared with those without COPD [<a href="#rid11">11</a>]. The rate of these major cardiovascular outcomes remained 25 percent higher in COPD patients (HR 1.25, 95% CI 1.23-1.37) even after adjusting for age, sex, smoking, sociodemographic characteristics, comorbidities, health care utilization, and laboratory testing typically used in robust cardiovascular risk models. Other large database studies have suggested that the increased cardiovascular risk is dose-dependent, with an approximately 20 to 30 percent relative increase in cardiovascular events and mortality for each fall in forced expiratory volume in 1 second (FEV<sub>1</sub>) by 10 percent predicted [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cause of increased cardiovascular risk in patients with COPD beyond the traditional risk factors is uncertain. In one study of over 1000 patients with COPD from the National Health and Nutrition Examination, factors associated with risk of cardiovascular disease included male sex, older age, smoking history, being overweight, history of blood transfusions, heart disease in close relatives, and higher leukocyte or monocyte counts [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk for cardiovascular events appears to be acutely elevated following COPD exacerbations. Among 5696 patients with COPD, an increased risk of myocardial infarction (incidence rate ratio [IRR] 2.58 [95% CI 2.26-2.95]) and stroke (IRR 1.97 [95% CI 1.66-2.33]) was noted in the days to weeks after an exacerbation of COPD [<a href="#rid7">7</a>].</p><p></p><p>Effect of COPD on morbidity and mortality in patients with CVD [<a href="#rid13">13-16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with COPD are more likely to have adverse outcomes after interventions for cardiovascular disease. For example, in a study of 3249 patients with an acute ST-elevation myocardial infarction, COPD was a strong independent predictor of the composite end-point of death or cardiogenic shock [<a href="#rid13">13</a>]. Similarly, among 14,346 patients who underwent percutaneous coronary intervention (PCI) at a single center, COPD was a significant independent risk factor for overall mortality, cardiac mortality, and myocardial infarction [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac explanations for these poorer outcomes are suggested by a separate study of patients undergoing PCI compared subjects with and without COPD (860 and 10,048, respectively) [<a href="#rid15">15</a>]. The patients with COPD had a lower mean ejection fraction and a greater number of significant coronary lesions. As in the studies above, the COPD group also carried a higher mortality rate and a greater rate of repeat revascularization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impact of COPD on vascular stiffness has also been examined. In a prospective study of 98 patients with stable COPD, 55 of whom experienced a subsequent exacerbation, increased arterial stiffness was associated with more frequent exacerbations, and arterial stiffness rose further during acute exacerbations [<a href="#rid17">17</a>]. The degree of arterial stiffness was also related to several inflammatory biomarkers in COPD.</p><p></p><p class="bulletIndent1">COPD is also a risk factor for supraventricular and ventricular arrhythmias. The risk factors for and management of arrhythmias in patients with COPD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">"Arrhythmias in COPD"</a>.)</p><p></p><p class="headingAnchor" id="H104142942"><span class="h1">EVALUATION AND DIAGNOSIS OF CHD IN PATIENTS WITH COPD</span><span class="headingEndMark"> — </span>The symptoms of dyspnea and chest tightness are common to COPD and coronary heart disease (CHD). In patients with known COPD, uncontrolled dyspnea and/or chest tightness could be due to refractory COPD or concomitant CHD. Due to the frequent co-existence of these diseases and the potential diagnostic uncertainty of the symptoms, physicians caring for patients with COPD need to have a low threshold for performing additional diagnostic testing to identify CHD.</p><p class="headingAnchor" id="H1797408178"><span class="h2">Myocardial ischemia</span><span class="headingEndMark"> — </span>Since exacerbations of both COPD and CHD are often signaled by dyspnea, patients and clinicians may find it challenging to know which disease requires urgent treatment. Classic symptoms of a COPD flare (eg, dyspnea, cough, wheezing, and change in sputum) may point correctly to the lung, while new electrocardiographic signs of ischemia may prove that the heart is the culprit. Alternatively, both organ systems may be involved and difficult to distinguish. (See  <a class="medical medical_review" href="/z/d/html/292.html" rel="external">"Approach to the adult with dyspnea in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p>For ambulatory patients with COPD and symptoms that could be attributable to myocardial ischemia, we typically perform a baseline electrocardiogram and <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> stress imaging, as exercise limitations may preclude exercise stress testing, and potential bronchoconstriction is often a contraindication to vasodilator radionuclide myocardial perfusion imaging. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/z/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a>.)</p><p>For patients presenting to the hospital with dyspnea and chest tightness, an elevated serum cardiac troponin frequently, but not always, indicates the presence of coronary artery disease. Among 242 patients admitted for an exacerbation of COPD, 24 had a raised troponin and 20 had chest pain and/or serial electrocardiogram (ECG) changes [<a href="#rid18">18</a>]. However, neither chest pain nor serial ECG changes were statistically associated with elevated troponin, suggesting that a raised troponin in the context of a COPD exacerbation is not necessarily indicative of myocardial injury. In a separate study, highly sensitive cardiac troponin (hs-cTnT) was measured in 50 patients admitted with an acute exacerbation of COPD and 124 stable patients in a pulmonary rehabilitation hospital [<a href="#rid19">19</a>]. The ratio of hs-cTnT in those with a COPD exacerbation was significantly higher than those with stable COPD, ratio 5.67 (95% CI 4.0-7.86). However, the specific determinants of hs-cTnT elevation were unclear, as neither hypoxic vasoconstriction nor underlying cardiovascular disease (CVD) were statistically associated with the increase in hs-cTnT. (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a> and  <a class="medical medical_review" href="/z/d/html/1469.html" rel="external">"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome"</a>.) </p><p class="headingAnchor" id="H1378749972"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Unrecognized heart failure can be a problem in the diagnosis and management of patients with COPD. The frequency of undiagnosed heart failure among ambulatory patients was examined in a cross-sectional study of 244 older adults with COPD [<a href="#rid20">20</a>]. Previously unrecognized heart failure was identified in 21 percent, and ischemic heart disease was judged to be the most common cause of heart failure. (See  <a class="medical medical_review" href="/z/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging", section on 'Differential diagnosis'</a>.) </p><p>Similarly, for patients presenting to the hospital, symptoms of an exacerbation of COPD overlap with acute worsening of heart failure. In a study examining the ability of N-terminal pro-brain natriuretic peptide (NT pro-BNP) and troponin T to differentiate an acute exacerbation of COPD from left heart dysfunction, 46 of the 148 patients (31 percent) were judged to have both a COPD exacerbation and heart failure [<a href="#rid21">21</a>]. </p><p>Thus, we have a low threshold to obtaining an echocardiogram and brain natriuretic peptide (BNP or N-terminal pro-BNP) in patients with a COPD exacerbation to make sure heart failure is not overlooked. However, caution is needed in the evaluation of BNP/NT-proBNP results in patients with severe COPD, as pulmonary hypertension can lead to an elevated BNP. In some patients a chest radiograph can help identify heart failure, but bullous emphysema can lead to an atypical appearance of heart failure. (See  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/122144.html" rel="external">"COPD exacerbations: Clinical manifestations and evaluation", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H12892415"><span class="h1">NONPHARMACOLOGIC THERAPIES</span><span class="headingEndMark"> — </span>A number of nonpharmacologic therapies may help reduce symptoms and improve quality of life in patients with concomitant COPD and CVD. These interventions have been evaluated in patients with either COPD or CVD but have not been examined extensively when both diseases are present.</p><p class="headingAnchor" id="H12892425"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>Smoking cessation is essential to improving outcomes in patients with comorbid COPD and CVD. Behavioral and pharmacologic interventions (eg, <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>) to help patients with smoking cessation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a> and  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a>.)</p><p><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a> replacement therapy is indicated for ambulatory patients with COPD despite the presence of CVD. The risk of coronary events (eg, cardiac arrest, myocardial infarction, admission to the hospital for CVD events) is lower among users of nicotine replacement than placebo. The issue of whether nicotine replacement can be started during a hospitalization for myocardial infarction has not been well studied, but cautious initiation during the hospitalization or at the time of discharge is thought to be reasonable. The use of nicotine replacement in patients with coronary artery disease (CAD) or acute myocardial infarction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1517.html" rel="external">"Cardiovascular effects of nicotine", section on 'Safety of nicotine replacement therapy'</a> and  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Smoking cessation'</a>.)</p><p class="headingAnchor" id="H12892461"><span class="h2">Cardiopulmonary rehabilitation</span><span class="headingEndMark"> — </span>A number of studies and systematic reviews have demonstrated the benefits of exercise training in patients with either COPD or CVD, but data are more limited regarding the benefit of exercise training in patients with comorbid COPD and CAD [<a href="#rid22">22</a>]. Observational studies have yielded conflicting results regarding the effect of comorbid CAD on the response to pulmonary rehabilitation. These studies are described in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation", section on 'Effect of comorbidities'</a>.)</p><p>Patients with COPD who have limited exercise capacity can often achieve an increase in their activity level with pulmonary rehabilitation. We typically refer patients to a pulmonary rehabilitation program, unless chest pain or myocardial ischemia is noted on an exercise pretest. These patients are referred for cardiac evaluation and possibly a cardiac rehabilitation program. (See  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a> and  <a class="medical medical_review" href="/z/d/html/1477.html" rel="external">"Cardiac rehabilitation programs", section on 'Summary'</a>.)</p><p class="headingAnchor" id="H12892433"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>Annual vaccination against influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is indicated for patients with COPD and/or CVD. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'COVID-19 and influenza vaccination'</a>.)</p><p>Vaccination against pneumococcus (<a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">pneumococcal polysaccharide vaccine</a> [PPSV23, Pneumovax]) should be offered to individuals with COPD and CVD. Revaccination with PPSV23 is advised at approximately 10-year intervals. Vaccination with pneumococcal conjugate vaccine (<a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">PCV13</a>, Prevnar) is individualized. Vaccination and revaccination schedules are described separately. (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p class="headingAnchor" id="H12892613"><span class="h2">Management of hypoxemia</span><span class="headingEndMark"> — </span>Among patients with COPD, hypoxemia (eg, pulse oxygen saturation ≤88 percent) may be present at rest or be precipitated by exercise, sleep-related hypopneas, a fit of coughing, or noncompliance with home oxygen. When added to the limitations to blood flow caused by coronary stenoses, episodes of hypoxemia can contribute to myocardial ischemia. (See  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes", section on 'Oxygen'</a>.)</p><p>The details of prescribing long-term oxygen therapy are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy", section on 'Prescribing oxygen'</a>.)</p><p class="headingAnchor" id="H3"><span class="h3">Effect of hypoxemia on the heart</span><span class="headingEndMark"> — </span>The duration and extent of hypoxemia necessary to produce ischemic changes resulting from coronary lesions is unknown. Mild or brief hypoxemia appears to be unimportant. This was illustrated in a study of 38 patients with ST depression on cardiac stress testing in whom three minutes of breathing a hypoxic mixture to produce an arterial oxygen saturation of 85 percent did not amplify the electrocardiographic signs of ischemia [<a href="#rid23">23</a>]. Myocardial ischemia appears more likely to worsen when the duration of hypoxemia is longer than five minutes or the degree of hypoxemia is severe (pulse oxygen saturation [SpO<sub>2</sub>] &lt;85 percent) [<a href="#rid24">24</a>].</p><p>Hypoxemia may also increase the risk of cardiac arrhythmia. A high incidence of ventricular and supraventricular arrhythmia, particularly multifocal atrial tachycardia (MAT), has been described in patients with COPD with either stable disease or an acute exacerbation [<a href="#rid25">25,26</a>]. Arrhythmias in COPD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/901.html" rel="external">"Multifocal atrial tachycardia"</a> and  <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">"Arrhythmias in COPD"</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Indications for supplemental oxygen</span><span class="headingEndMark"> — </span>Supplemental oxygen therapy can correct hypoxemia that is associated with stable COPD or a COPD exacerbation. Supplemental oxygen therapy can also relieve hypoxic pulmonary vasoconstriction and reverse tissue hypoxia. The enhanced oxygen content of arterial blood maintains total body oxygen delivery and allows the cardiac output to fall, reducing left ventricular work. This latter effect is probably one of the reasons that long-term supplemental oxygen improves survival in patients with COPD [<a href="#rid27">27-29</a>]. (See  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy", section on 'Benefits'</a>.) </p><p>Interestingly, the benefit of oxygen in patients with moderate resting desaturation (89 to 93 percent) has been questioned [<a href="#rid30">30</a>]. In this study of 738 patients randomized to receive supplemental oxygen or no supplemental oxygen, there were no differences in time to death or first hospitalization.</p><p>Current indications for continuous long-term oxygen therapy include:</p><p class="bulletIndent1"><span class="glyph">●</span>PaO<sub>2</sub> ≤55 mmHg or SpO<sub>2</sub> ≤88 percent during rest</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PaO<sub>2</sub> between 56 to 59 mmHg (SpO<sub>2</sub> of 89 percent) combined with evidence of cor pulmonale, right heart failure, or erythrocytosis (hematocrit &gt;56 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PaO<sub>2</sub> &gt;60 mmHg or SpO<sub>2</sub> &gt;90 percent with "compelling medical justification"; including significant coronary heart disease or active cardiac ischemia</p><p></p><p>Long-term oxygen therapy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a>.)</p><p>Oxygen supplementation may raise the PaCO<sub>2</sub> slightly in hypercapnic patients, but this is generally well tolerated. The risks of withholding oxygen or giving it too sparingly in these groups significantly outweigh any detrimental effects of higher PaCO<sub>2</sub> [<a href="#rid27">27-29,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">"The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure"</a>.)</p><p class="headingAnchor" id="H4096341"><span class="h2">Noninvasive positive pressure ventilation</span><span class="headingEndMark"> — </span>Noninvasive positive pressure ventilation (NPPV) can provide temporary ventilatory support in selected patients with acute cardiogenic pulmonary edema or acute hypercapnic respiratory failure due to a COPD exacerbation. It is an attractive option for patients who have severe dyspnea that may be due to COPD or CVD, buying additional time for diagnostic studies (eg, to determine whether symptoms are due to COPD, CVD, or both) and empiric therapy. (See  <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT OF COPD IN PATIENTS WITH CVD</span><span class="headingEndMark"> — </span>The mainstays of treatment for COPD include the inhaled anticholinergic agents, inhaled selective beta-2 agonists, and inhaled glucocorticoids; <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">roflumilast</a> and <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> are less commonly used. For patients with stable coronary artery disease (CAD), we treat symptomatic COPD with the same agents and doses that we would for someone without CVD, despite some concerns about increased CVD risk as noted below. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p class="headingAnchor" id="H81300262"><span class="h2">Inhaled anticholinergic medications</span><span class="headingEndMark"> — </span>An inhaled short-acting anticholinergic (muscarinic) agent (eg, <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>) is suggested as an alternative to inhaled short-acting beta-adrenergic agonists (SABAs) or in combination with a SABA for acute symptoms of COPD. Long-acting anticholinergic agents (eg, <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a>, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrronium</a>, <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">umeclidinium</a>) are recommended, regardless of underlying CVD, for patients with COPD who have frequent symptoms or exacerbations [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p>Some studies have raised concern about a potential increase in cardiovascular risk with these agents, but other studies are reassuring. This concern should be balanced against the <strong>known</strong> benefits of these inhaled anticholinergic agents (eg, reduced frequency of exacerbations, fewer hospitalizations, and improved dyspnea). This topic is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">"Role of muscarinic antagonist therapy in COPD"</a> and  <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">"Role of muscarinic antagonist therapy in COPD", section on 'Cardiovascular effects'</a>.)</p><p>Two systematic reviews and meta-analyses raised concerns that <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, when administered by soft mist inhaler (eg, Spiriva Respimat), might be associated with increased mortality [<a href="#rid32">32,33</a>]. However, subsequent data from the TIOtropium Safety and Performance In Respimat (TIOSPIR) trial was reassuring except for patients with unstable cardiovascular conditions who were excluded from the trial [<a href="#rid34">34</a>]. These studies are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">"Role of muscarinic antagonist therapy in COPD"</a> and  <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">"Role of muscarinic antagonist therapy in COPD", section on 'Potential risks'</a>.)</p><p class="headingAnchor" id="H4096480"><span class="h2">Beta-2 agonists</span><span class="headingEndMark"> — </span>The inhaled beta-2 agonists (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a>, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">indacaterol</a>, <a class="drug drug_general" data-topicid="96482" href="/z/d/drug information/96482.html" rel="external">olodaterol</a>, <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>, vilanterol) are relatively selective for beta-2 adrenergic receptors. However, the possibility has been raised that mild beta-1 activity associated with these agents might cause the following adverse effects in patients with COPD and CVD:</p><p class="bulletIndent1"><span class="glyph">●</span>The possible induction of arrhythmias by stimulation of cardiac beta-adrenoreceptors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reflex activation of adrenergic mechanisms by causing peripheral vasodilation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Downregulation of myocardial beta-2 receptors, potentially worsening heart failure associated with left ventricular systolic dysfunction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provocation of hypokalemia by intracellular translocation of potassium or hypoxemia through worsened matching of ventilation and perfusion</p><p></p><p class="headingAnchor" id="H27291990"><span class="h3">Short-acting beta-agonists</span><span class="headingEndMark"> — </span>Short-acting inhaled beta-agonists (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, <a class="drug drug_general" data-topicid="10215" href="/z/d/drug information/10215.html" rel="external">levalbuterol</a>) are the preferred bronchodilators for treatment of acute symptoms of COPD, based on their rapid onset of action. This choice is unaffected by the presence of CAD. It is reassuring that among 12,090 patients age 55 or older with COPD, short-acting inhaled beta-agonists did not increase the risk of fatal or nonfatal myocardial infarction [<a href="#rid35">35</a>]. The management of acute exacerbations of COPD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management", section on 'Hospital-based bronchodilator therapies'</a>.)</p><p class="headingAnchor" id="H27291983"><span class="h3">Long-acting beta-agonists</span><span class="headingEndMark"> — </span>Inhaled long-acting beta-agonists (LABAs) are widely used for treatment of COPD; data are generally reassuring regarding their safety in patients with CVD [<a href="#rid36">36,37</a>]. Several studies have specifically evaluated the cardiovascular effects of LABAs. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular events</strong> – The Toward a Revolution in COPD Health (TORCH) trial compared <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a> alone, <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> alone, salmeterol plus fluticasone, and placebo in 6112 patients with COPD over three years [<a href="#rid38">38</a>]. The frequency of cardiac events was not increased in the salmeterol alone group or the salmeterol plus fluticasone group [<a href="#rid39">39</a>]. In contrast, a nested case control study found an increased risk of cardiovascular events (ie, emergency department visit or hospitalization for coronary heart disease, cardiac arrhythmia, heart failure, or ischemic stroke) among 37,719 patients with COPD and new use of a LABA (adjusted OR 1.5, 95% CI 1.4-1.7), while prevalent use was associated with a 9 percent decrease in risk [<a href="#rid40">40</a>]. Similarly, a large database study of over 180,000 patients found that initiation of LABA, SABA, or ICS/LABA in patients with COPD was associated with increased risk for cardiovascular events compared with patients with COPD initiated on SAMAs, but not compared with those initiated on LAMAs [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">There are some important limitations to these studies. The TORCH trial may not be widely generalizable due to exclusion of patients with underlying cardiovascular disease. In addition, the case-control and database designs are limited by potential confounding. Therefore, we advise caution when prescribing beta-agonists to people with severe and/or symptomatic coronary artery disease. Thorough patient characterization and risk stratification prior to the use of LABAs may reduce the risk of cardiovascular events in patients with coronary artery disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – Some but not all studies have suggested that beta-2 agonists may have an adverse effect in patients with left ventricular dysfunction. In a review of 1529 patients with left ventricular systolic dysfunction (by echocardiography or radionuclide ventriculography), the relative risk of hospitalization for heart failure followed a dose-response relationship with the use of inhaled beta-agonists [<a href="#rid42">42</a>]. In contrast, a retrospective study of 1294 subjects attending a heart failure disease management program did not find an increase in mortality associated with beta-2 agonist use (HR 1.0, 95% CI 0.8-1.4) after adjusting for age, sex, smoking, medications, and severity of co-morbidities [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmias</strong> – While beta-2 adrenergic agonists have the potential to increase heart rate and may increase cardiac arrhythmias via nonselective beta-adrenergic effects, a number of studies have shown a very low to no increased risk of serious arrhythmias with these medications. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">"Arrhythmias in COPD", section on 'Beta-adrenergic agonists'</a>.)</p><p></p><p class="headingAnchor" id="H343978626"><span class="h2">Combination LAMA-LABA</span><span class="headingEndMark"> — </span>The combination of long-acting muscarinic agent (LAMA) plus a LABA is suggested as an initial regimen for patients with COPD with exacerbations or burdensome respiratory symptoms  (<a class="graphic graphic_algorithm graphicRef54300" href="/z/d/graphic/54300.html" rel="external">algorithm 1</a>). Data regarding cardiovascular safety of the individual agents are mixed, but largely reassuring [<a href="#rid1">1,39,44</a>], as described above. (See <a class="local">'Inhaled anticholinergic medications'</a> above and <a class="local">'Long-acting beta-agonists'</a> above.)</p><p>Data from clinical trials and systematic reviews of combination bronchodilator inhalers are more limited and not entirely consistent, suggesting heterogeneous effects in different trial populations:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review comparing the combination of a LABA plus <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a> with a LABA or tiotropium alone found no significant increase in serious adverse events with the combination inhaler, although separate data on cardiovascular outcomes was not provided [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of trials comparing LAMA-LABA and LABA-glucocorticoid inhalers for stable COPD (11 studies, 9839 participants), a nonsignificant decrease in serious adverse events was noted in the LAMA-LABA group [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, another large systemic review (42 studies, over 71,000 patients with stable COPD) found that while dual LAMA-LABA therapy did not demonstrate increased risk for major adverse cardiac events compared with LAMA alone, LABA alone, or placebo, there was a small increased risk compared with combined LABA and inhaled glucocorticoid (1.6 versus 1.3 percent, RR 1.4, 95% CI 1.1-1.8) [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Combination inhaled bronchodilators plus glucocorticoid</span><span class="headingEndMark"> — </span>The evidence suggests that the addition of inhaled glucocorticoids to LABAs or dual bronchodilator therapy is safe [<a href="#rid38">38,39,47-52</a>], albeit a small, not statistically significant, increase in cardiovascular risk has been reported with combined LABA and inhaled glucocorticoid therapy [<a href="#rid47">47</a>]. The following studies support this conclusion, although only the first one was specifically performed in patients with CVD [<a href="#rid50">50</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In the three-year Study to Understand Mortality and MorbidITy (SUMMIT), the effect of <a class="drug drug_general" data-topicid="89424" href="/z/d/drug information/89424.html" rel="external">fluticasone furoate-vilanterol</a> (100 mcg-25 mcg) combination was compared with the individual components and placebo in 16,590 patients with moderate COPD (FEV<sub>1</sub> between 50 and 70 percent of predicted) and risk factors for or known CVD [<a href="#rid50">50</a>]. Relative to placebo, the combination inhaler did not affect all-cause mortality (hazard ratio [HR] 0.9, 95% CI 0.7-1.0) or composite cardiovascular events (HR 0.9, 95% CI 0.75-1.1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis (10 studies, 10,680 participants) that compared combination inhaled LABA plus glucocorticoid with inhaled LABA alone in COPD, there was no significant difference in mortality (OR 0.9, 95% CI 0.8-1.1) [<a href="#rid48">48</a>]. However, underlying cardiovascular disease was an exclusion criterion for participation, and the rate of cardiovascular events was not examined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the IMPACT and ETHOS trials of combination LAMA, LABA, and inhaled glucocorticoids in patients with stable COPD, there was reduced all-cause mortality in the groups receiving triple therapy compared with dual bronchodilator therapy alone [<a href="#rid51">51,52</a>]. (See  <a class="medical medical_review" href="/z/d/html/1449.html" rel="external">"Role of inhaled glucocorticoid therapy in stable COPD", section on 'Mortality'</a> and  <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">"Stable COPD: Follow-up pharmacologic management", section on 'Exacerbations on LAMA-LABA therapy'</a>.)</p><p></p><p class="bulletIndent1">Although not statistically significant, there was also a trend towards reductions in cardiovascular mortality in the triple therapy compared with dual therapy arm in both trials (0.5 versus 1.4 percent in ETHOS; 0.6 versus 1.0 percent in IMPACT).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systemic review and meta-analysis, there was a similar risk of major adverse cardiovascular events in patients receiving triple therapy with LAMA-LABA-glucocorticoid compared with those receiving dual LAMA-LABA therapy (1.6 versus 1.8 percent, RR 0.8, 95%CI 0.6-1.2) based on three studies of nearly 14,000 patients [<a href="#rid47">47</a>]. However, patients receiving LAMA-LABA-glucocorticoid combination therapy did have increased rates of cardiovascular events compared with LABA-glucocorticoid alone (1.6 versus 1.4 percent, RR 1.3, 95% CI 1.0-1.7) in nine studies of 21,000 patients.</p><p></p><p>The roles of combined LABA-glucocorticoid and LAMA-LABA-glucocorticoid inhaled medications in COPD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Alternative approaches'</a> and  <a class="medical medical_review" href="/z/d/html/122160.html" rel="external">"Stable COPD: Follow-up pharmacologic management", section on 'Persistent exacerbations with or without dyspnea'</a>.)</p><p class="headingAnchor" id="H81298178"><span class="h2">Roflumilast</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">Roflumilast</a> is a phosphodiesterase-4 inhibitor that is approved for use in patients with a history of COPD exacerbations. It provides a modest improvement in pulmonary function. Initial studies suggest that roflumilast does not substantially increase cardiovascular outcomes of death and nonfatal myocardial infarction but may increase the frequency of atrial fibrillation. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a pooled analysis of 14 trials lasting from 12 to 52 weeks, the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and stroke was lower among patients receiving <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">roflumilast</a> compared with placebo (HR 0.65, 95% CI 0.45-0.9), although none of the individual components reached statistical significance [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of eight trials (8696 patients), atrial fibrillation was more frequent in patients on <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">roflumilast</a> than placebo (0.4 versus 0.2 percent) [<a href="#rid54">54</a>]. Atrial fibrillation and other supraventricular arrhythmias occurred in less than 2 percent of patients in previous clinical trials with roflumilast, but these trials may not have included patients with known CVD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant administration of <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">roflumilast</a> and <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> to healthy men did not result in adverse cardiovascular effects [<a href="#rid55">55</a>]. </p><p></p><p>The use of <a class="drug drug_general" data-topicid="16465" href="/z/d/drug information/16465.html" rel="external">roflumilast</a> in COPD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Phosphodiesterase-4 inhibitors (Roflumilast)'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Theophylline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> is generally avoided in patients with CAD. While occasionally used in patients with COPD for its mild bronchodilating effects and a possible improvement in exercise performance, it has a narrow therapeutic index and is associated with tachycardia and arrhythmias. Administration of theophylline is plagued by an appreciable incidence of side effects, even when serum drug concentrations are in the low therapeutic range. These adverse effects include tachycardia and palpitations, in addition to gastrointestinal upset and headaches. (See  <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">"Theophylline poisoning"</a>.)</p><p>Evidence of an adverse effect of <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> in patients with CVD is largely indirect, but suggests an increased risk of dose-related atrial and ventricular arrhythmias [<a href="#rid56">56-58</a>]. The contribution of theophylline to the development of arrhythmias in patients with COPD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1454.html" rel="external">"Arrhythmias in COPD", section on 'Theophylline'</a>.)</p><p class="headingAnchor" id="H81297784"><span class="h1">TREATMENT OF CVD IN PATIENTS WITH COPD</span><span class="headingEndMark"> — </span>The management of symptomatic CAD in patients with COPD generally follows the same guidelines as for patients without COPD, except that we avoid nonselective beta-blockers in patients with COPD due to concerns about the induction of clinically important bronchoconstriction by nonselective agents. Instead, we typically use a cardioselective beta-blocker (eg, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> or <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>) [<a href="#rid59">59</a>]. Alternative agents for the treatment of ischemia, arrhythmias, or hypertension that do not carry the risk of bronchoconstriction can also be considered. (See  <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a> and  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a>.)</p><p>When initiating a selective beta-blocker in a patient with COPD, careful guidance should be given regarding new symptoms (eg, dyspnea, exercise intolerance, cough) or changes in medication use patterns (eg, increased need for a beta-agonist inhaler) that would prompt reevaluation. </p><p>The role of beta-blockers in patients with acute myocardial infarction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy", section on 'Contraindications'</a>.)</p><p class="headingAnchor" id="H97494869"><span class="h2">Effects of beta-blockers on mortality and COPD exacerbations</span><span class="headingEndMark"> — </span>Cardioselective beta-blocker therapy does not appear to worsen mortality in COPD patients, but the impact on exacerbations is less clear, particularly among those lacking cardiac indications.</p><p>In large trials of long-acting bronchodilator therapies, concomitant cardioselective beta-blocker therapy did not appear to reduce the respiratory benefits of inhaled long-acting beta-agonists [<a href="#rid60">60,61</a>]. In particular, the use of beta-blockers for cardiovascular indications did not impact rates of COPD exacerbations or mortality.</p><p>Observational data implicate a potential benefit for beta-blockade on these outcomes for some patients with COPD [<a href="#rid62">62-67</a>]; however, beta-blockade was <strong>not</strong> beneficial in a randomized trial in COPD patients without a cardiovascular indication [<a href="#rid68">68</a>]. Although the data in aggregate suggest a possible protective effect of beta-blockade in patients with COPD and cardiovascular disease, there may have been selection bias in observational studies based on patient selection for beta blocker use. Examples of studies in different settings include: </p><p class="bulletIndent1"><span class="glyph">●</span>Postmyocardial infarction – Among 10,884 patients with COPD discharged from Danish hospitals after an acute myocardial infarction, beta-blocker use was associated with a lower risk of acute exacerbation of COPD over at least a year of follow-up (multivariable-adjusted HR 0.78, 95% CI 0.74–0.83) independent of COPD severity or exacerbation history [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any indication for beta blockers – In an observational cohort study of 2230 COPD patients, the use of beta-blockers was associated with lower hazard ratios for both mortality (HR 0.68, 95% CI 0.56-0.83) and exacerbations of COPD (HR 0.71, 95% CI 0.60-0.83) [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients without other indications – Five hundred and thirty two patients with moderate-severe COPD and no other indication for beta blocker therapy were randomly assigned to receive extended-release <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> or placebo [<a href="#rid68">68</a>]. The metoprolol group experienced an increased risk of exacerbation leading to hospitalization (92 versus 58 hospitalizations, rate ratio 1.6, 95% CI 1.1-2.4). This severe exacerbation risk was not mediated by changes in lung function or bronchodilator responsiveness in the metoprolol group [<a href="#rid70">70</a>]. Those taking metoprolol also had a time until first exacerbation of 202 days, versus 222 days among those not receiving metoprolol, a difference that did not achieve statistical significance (HR 1.05) [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H97494824"><span class="h2">Effect of cardioselective beta blockers on lung function</span><span class="headingEndMark"> — </span>While nonselective beta blockade can precipitate bronchospasm in those who are predisposed, selective beta-1 blockers (eg, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> or <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>) are generally safe in patients with COPD, even when there is a bronchospastic component [<a href="#rid59">59,62,71-76</a>]. </p><p>The effect of cardioselective beta-blockers was assessed in a meta-analysis of randomized trials in which single-dose or long-term cardioselective beta blockers were administered to nearly 400 patients with either asthma or COPD and reversible bronchoconstriction (&gt;15 percent improvement in forced expiratory volume in one second (FEV<sub>1</sub>) following bronchodilator treatment) [<a href="#rid77">77</a>]. The following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Single-dose use was associated with an 8 percent decrease in FEV<sub>1</sub>, but a 5 to 9 percent increase in bronchodilator response</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sustained use was not associated with a significant change in baseline FEV<sub>1</sub></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term therapy did not increase respiratory symptoms or the use of inhaled beta-agonists</p><p></p><p>In a study of <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> inhalation challenge in patients with COPD, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> (80 mg/day) caused a reduction in FEV<sub>1</sub> and in the bronchodilating effect of <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> in addition to an increase in airway hyperresponsiveness to methacholine [<a href="#rid78">78</a>]. In contrast, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> (100 mg/day) did not affect FEV<sub>1</sub> or responsiveness to formoterol but did increase airway hyperresponsiveness. </p><p class="headingAnchor" id="H97494884"><span class="h2">Effect of combination beta and alpha blockers on lung function</span><span class="headingEndMark"> — </span>Combined beta and alpha blockers are sometimes indicated for patients with CAD and heart failure. (See  <a class="medical medical_review" href="/z/d/html/1466.html" rel="external">"Beta blockers in the management of chronic coronary syndrome", section on 'Agents with alpha blocking activity'</a>.)</p><p>Data regarding the effects of combined beta and alpha adrenergic blockade (eg, <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a>, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>) in patients with COPD are limited, but include the following [<a href="#rid79">79</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>The effect of <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a> (nonselective beta-blocker with alpha antagonism) on lung function was compared with the selective beta-blockers <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> and <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a> in 35 patients with COPD and heart failure [<a href="#rid80">80</a>]. FEV<sub>1</sub> was lowest with carvedilol and highest with bisoprolol (carvedilol 1.85 [95% CI, 1.67-2.03]; metoprolol 1.94 [95% CI, 1.73-2.14]; bisoprolol 2.0 [95% CI, 1.79-2.22]), although the six-minute walk distance was not different. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small series of 11 patients with COPD and hypertension, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a> (nonselective beta-blocker with alpha antagonism) up to 1200 mg/day caused no significant changes in FEV<sub>1</sub> or forced expiratory flow (forced expiratory flow [FEF] 25 to 75) [<a href="#rid81">81</a>]. Likewise, in a report of 14 patients with COPD treated with <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a> 25 mg PO twice daily for heart failure, no changes were noted in FEV<sub>1</sub>, vital capacity, or peak oxygen consumption with exercise [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Celiprolol, a selective beta-1 blocker with mild beta-2 agonist and alpha-2 antagonist properties (not available in the United States), did not result in increased pulmonary symptoms, a decrease in FEV<sub>1</sub>, or increased airway hyperresponsiveness to <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> when given to four patients with mild-to-moderate COPD [<a href="#rid78">78</a>]. In the same study, FEV<sub>1</sub> was significantly lower after four days of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, compared with <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> or placebo, and the bronchodilator response to <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> was blunted after propranolol, but not metoprolol, celiprolol, or placebo. </p><p></p><p>Further study is needed to clarify the role of combined alpha and beta blockers in the management of cardiovascular disease (CVD) in patients with COPD.</p><p class="headingAnchor" id="H21522940"><span class="h2">Effect of statins on COPD exacerbations</span><span class="headingEndMark"> — </span>Almost all patients with known CVD should be treated with a statin medication (see  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>). While statins have been postulated to have an additional benefit of reducing COPD exacerbations, the evidence is conflicting [<a href="#rid83">83-85</a>]. (See  <a class="medical medical_review" href="/z/d/html/122145.html" rel="external">"COPD exacerbations: Prognosis, discharge planning, and prevention", section on 'Ineffective interventions'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Revascularization in patients with COPD</span><span class="headingEndMark"> — </span>The presence of COPD affects decision-making in patients with possible indications for coronary artery bypass grafting (CABG), because of concerns about excess postoperative morbidity and mortality in this population [<a href="#rid86">86-89</a>]. Expected post-CABG mortality ranges from 2 to 4 percent for all patients and is about 1 percent for those at lowest risk. Among 11,217 patients who underwent CABG, increasing severity of COPD based on impairment in FEV<sub>1</sub> correlated with an increasing frequency of postoperative complications and severe COPD was associated with early mortality, adjusted OR 2.31 (95% CI 1.23-4.36) [<a href="#rid86">86</a>]. In contrast to patients with severe COPD, post-CABG mortality for patients with mild or moderate COPD is similar to the rate among those without COPD [<a href="#rid90">90</a>]. In a database study from Taiwan of 706 individuals with COPD and almost 15,000 without, COPD did not increase the risk of mortality, but did increase the risk of postoperative pneumonia and acute respiratory failure [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery"</a>.)</p><p>Patients with COPD who undergo CABG are also at increased risk of perioperative morbidity, particularly pulmonary complications that result from sternotomy and use of cardiopulmonary bypass [<a href="#rid86">86,91</a>]. Patients with significant COPD who survive the early postoperative period after CABG appear to have improved quality of life [<a href="#rid91">91</a>]. </p><p>For patients who require CABG, preoperative and postoperative optimization of pulmonary function and careful monitoring for rhythm disturbances seem advisable. If available, minimally invasive CABG may represent a useful therapeutic option, although it has not been specifically assessed in patients with COPD. (See  <a class="medical medical_review" href="/z/d/html/6970.html" rel="external">"Strategies to reduce postoperative pulmonary complications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1556.html" rel="external">"Coronary artery bypass surgery: Perioperative medical management"</a> and  <a class="medical medical_review" href="/z/d/html/1558.html" rel="external">"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Clinical use"</a> and  <a class="medical medical_review" href="/z/d/html/1584.html" rel="external">"Early cardiac complications of coronary artery bypass graft surgery", section on 'Arrhythmias'</a>.)</p><p>Among patients with CVD and COPD, percutaneous coronary interventions (eg, balloon angioplasty or stent placement) are associated with an increased mortality and rates of repeat revascularization within one year compared with patients without COPD [<a href="#rid15">15</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Using the National Heart, Lung, and Blood Institute Dynamic Registry, the outcomes following percutaneous coronary interventions were compared in patients with (860) or without (10,048) COPD. Patients with COPD had a significantly increased risk of death (hazard ratio 1.30, 95% CI 1.01-1.67). Of note, patients with COPD were also significantly less likely to be prescribed beta-blockers at discharge. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of over 4600 cases comparing bare-metal stents with drug-eluting stents, patients with COPD had higher rates of major adverse cardiac events (15.2 versus 8.1 percent), all-cause death (11.7 versus 2.4 percent), cardiac death (5.7 versus 1.2 percent), MI (3.5 versus 1.9 percent), stent thrombosis (2.5 versus 0.9 percent), and major bleeding (4.2 versus 2.1 percent) [<a href="#rid92">92</a>]. In all instances the drug-eluding stent patients had better outcomes than the bare-metal patients suggesting that drug-eluting stents be used in patients with COPD.</p><p></p><p>Although outcomes after percutaneous coronary intervention (PCI) or CABG have not been directly compared in patients with COPD, PCI is a reasonable alternative for some patients who would otherwise receive a recommendation for CABG. We suggest that the decision to choose one revascularization therapy be made after the patient has been fully informed of the relative benefits and risks of each approach.</p><p class="headingAnchor" id="H3450106820"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H12892306"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD) share tobacco abuse as a risk factor and commonly coexist. The presence of either disease can adversely affect outcomes of the other. (See <a class="local">'COPD/CVD relationship'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with concomitant severe COPD and CAD, a number of nonpharmacologic therapies (eg, smoking cessation, pulmonary rehabilitation, vaccination against influenza and pneumococcus, supplemental oxygen) are indicated to reduce symptoms, improve quality of life, and prevent exacerbations, as in patients with COPD alone. (See <a class="local">'Nonpharmacologic therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, the pharmacologic management of comorbid COPD and cardiovascular disease (CVD) follows the same guidelines as for patients without comorbid disease. (See <a class="local">'Treatment of COPD in patients with CVD'</a> above and <a class="local">'Treatment of CVD in patients with COPD'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with COPD and CAD, we recommend that a short-acting bronchodilator be prescribed for use as-needed for relief of acute symptoms of COPD (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Either a short-acting beta-agonist, a short-acting anticholinergic, or a combination can be used, depending on patient preference. For patients on a long-acting anticholinergic agent, a short-acting beta-agonist is used instead of a short-acting anticholinergic agent, for quick relief of COPD symptoms. (See <a class="local">'Short-acting beta-agonists'</a> above and <a class="local">'Inhaled anticholinergic medications'</a> above and  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management", section on 'Rescue bronchodilator therapy for all patients'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concern has been raised regarding possible adverse cardiovascular effects of the inhaled long-acting beta-agonists (LABAs) and also the long-acting anticholinergic medications (LAMAs), although the data is largely reassuring. For patients with concomitant COPD and CVD, we advise following guideline-based therapy for COPD; many patients with COPD require therapy with both agents. (See <a class="local">'Treatment of COPD in patients with CVD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of combination long-acting beta-agonist-glucocorticoid inhalers does not adversely affect mortality in COPD, although data are limited regarding specific effects on cardiovascular outcomes. (See <a class="local">'Combination inhaled bronchodilators plus glucocorticoid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with COPD and comorbid CVD, we recommend using a cardioselective beta blocker (eg, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> or <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>), rather than a nonselective beta-blocker (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). For those patients who also have heart failure, use of a combined beta and alpha blocker (eg, <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">carvedilol</a>, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>) appears to have minimal adverse effect on COPD, although data are limited. (See <a class="local">'Effect of cardioselective beta blockers on lung function'</a> above and <a class="local">'Effect of combination beta and alpha blockers on lung function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardioselective beta-blocker therapy does not appear to worsen mortality in COPD patients, but the impact on exacerbations is less clear, particularly among those lacking cardiac indications. (See <a class="local">'Effects of beta-blockers on mortality and COPD exacerbations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After initiation of beta-blocker therapy, patients are given careful guidance regarding new symptoms (eg, dyspnea, exercise intolerance, cough) or increased need for a beta-agonist inhaler that should prompt reevaluation. (See <a class="local">'Treatment of CVD in patients with COPD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe COPD who meet cardiovascular criteria for coronary artery bypass grafting (CABG), percutaneous coronary intervention is often preferred if there is a reasonable likelihood of success. (See <a class="local">'Revascularization in patients with COPD'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who require CABG, preoperative optimization of pulmonary function and careful monitoring for cardiac arrhythmias are advised. A minimally invasive surgical approach may be advisable. (See  <a class="medical medical_review" href="/z/d/html/1558.html" rel="external">"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Clinical use", section on 'Patient selection'</a>.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65:956.</a></li><li><a class="nounderline abstract_t">Reed RM, Eberlein M, Girgis RE, et al. Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. Am J Med 2012; 125:1228.e13.</a></li><li><a class="nounderline abstract_t">Enriquez JR, de Lemos JA, Parikh SV, et al. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. Am Heart J 2013; 165:43.</a></li><li><a class="nounderline abstract_t">Chen H, Luo X, Du Y, et al. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013-2018. BMC Pulm Med 2023; 23:318.</a></li><li><a class="nounderline abstract_t">Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3:631.</a></li><li><a class="nounderline abstract_t">Rothnie KJ, Connell O, Müllerová H, et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2018; 15:935.</a></li><li><a class="nounderline abstract_t">McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62:411.</a></li><li><a class="nounderline abstract_t">Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2:8.</a></li><li><a class="nounderline abstract_t">Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med 2018; 198:51.</a></li><li><a class="nounderline abstract_t">Maclagan LC, Croxford R, Chu A, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J 2023; 62.</a></li><li><a class="nounderline abstract_t">Qu S, Zhu J. A Nomogram for Predicting Cardiovascular Diseases in Chronic Obstructive Pulmonary Disease Patients. J Healthc Eng 2022; 2022:6394290.</a></li><li><a class="nounderline abstract_t">Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol 2010; 106:305.</a></li><li><a class="nounderline abstract_t">Konecny T, Somers K, Orban M, et al. Interactions between COPD and outcomes after percutaneous coronary intervention. Chest 2010; 138:621.</a></li><li><a class="nounderline abstract_t">Enriquez JR, Parikh SV, Selzer F, et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest 2011; 140:604.</a></li><li><a class="nounderline abstract_t">Campo G, Guastaroba P, Marzocchi A, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013; 144:750.</a></li><li><a class="nounderline abstract_t">Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:1091.</a></li><li><a class="nounderline abstract_t">McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012; 39:1097.</a></li><li><a class="nounderline abstract_t">Søyseth V, Bhatnagar R, Holmedahl NH, et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013; 99:122.</a></li><li><a class="nounderline abstract_t">Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26:1887.</a></li><li><a class="nounderline abstract_t">Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006; 174:990.</a></li><li><a class="nounderline abstract_t">Reid WD, Yamabayashi C, Goodridge D, et al. Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews. Int J Chron Obstruct Pulmon Dis 2012; 7:297.</a></li><li><a class="nounderline abstract_t">Entwistle MD, Sommerville D, Tandon AP, Jones JG. Effect of hypoxaemia on the resting electrocardiogram (ECG) in patients with cardiac ischaemia. Ann Acad Med Singapore 1994; 23:460.</a></li><li><a class="nounderline abstract_t">Gill NP, Wright B, Reilly CS. Relationship between hypoxaemic and cardiac ischaemic events in the perioperative period. Br J Anaesth 1992; 68:471.</a></li><li><a class="nounderline abstract_t">Shih HT, Webb CR, Conway WA, et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 1988; 94:44.</a></li><li><a class="nounderline abstract_t">Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98:272.</a></li><li><a class="nounderline abstract_t">Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.</a></li><li><a class="nounderline abstract_t">Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.</a></li><li><a class="nounderline abstract_t">Petty TL. Supportive therapy in COPD. Chest 1998; 113:256S.</a></li><li><a class="nounderline abstract_t">Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016; 375:1617.</a></li><li><a class="nounderline abstract_t">Schmidt, GA, Hall, JB . Oxygen therapy and hypoxic drive to breathe: Is there danger in the patient with COPD? Intensive Crit Care Dig 1989; 8:124.</a></li><li><a class="nounderline abstract_t">Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342:d3215.</a></li><li><a class="nounderline abstract_t">Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; :CD009285.</a></li><li><a class="nounderline abstract_t">Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369:1491.</a></li><li><a class="nounderline abstract_t">Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58:43.</a></li><li><a class="nounderline abstract_t">Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817.</a></li><li><a class="nounderline abstract_t">Tranfa CM, Pelaia G, Grembiale RD, et al. Short-term cardiovascular effects of salmeterol. Chest 1998; 113:1272.</a></li><li><a class="nounderline abstract_t">Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775.</a></li><li><a class="nounderline abstract_t">Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65:719.</a></li><li><a class="nounderline abstract_t">Wang MT, Liou JT, Lin CW, et al. Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study. JAMA Intern Med 2018; 178:229.</a></li><li><a class="nounderline abstract_t">Amegadzie JE, Gamble JM, Farrell J, Gao Z. Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. Int J Chron Obstruct Pulmon Dis 2022; 17:1205.</a></li><li><a class="nounderline abstract_t">Au DH, Udris EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003; 123:1964.</a></li><li><a class="nounderline abstract_t">Bermingham M, O'Callaghan E, Dawkins I, et al. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 2011; 13:885.</a></li><li><a class="nounderline abstract_t">Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20.</a></li><li><a class="nounderline abstract_t">Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; :CD008989.</a></li><li><a class="nounderline abstract_t">Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2017; 2:CD012066.</a></li><li><a class="nounderline abstract_t">Yang M, Li Y, Jiang Y, et al. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J 2023; 61.</a></li><li><a class="nounderline abstract_t">Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; :CD006829.</a></li><li><a class="nounderline abstract_t">Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834.</a></li><li><a class="nounderline abstract_t">Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387:1817.</a></li><li><a class="nounderline abstract_t">Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med 2021; 203:553.</a></li><li><a class="nounderline abstract_t">Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2020; 201:1508.</a></li><li><a class="nounderline abstract_t">White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013; 144:758.</a></li><li><a class="nounderline abstract_t">Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 2013; 7:13.</a></li><li><a class="nounderline abstract_t">de Mey C, Nassr N, Lahu G. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study. BMC Clin Pharmacol 2011; 11:7.</a></li><li><a class="nounderline abstract_t">Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 1990; 98:672.</a></li><li><a class="nounderline abstract_t">Bittar G, Friedman HS. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants. Chest 1991; 99:1415.</a></li><li><a class="nounderline abstract_t">Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154:1598.</a></li><li><a class="nounderline abstract_t">Foresi A, Cavigioli G, Signorelli G, et al. Is the use of beta-blockers in COPD still an unresolved dilemma? Respiration 2010; 80:177.</a></li><li><a class="nounderline abstract_t">Dransfield MT, McAllister DA, Anderson JA, et al. β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Ann Am Thorac Soc 2018; 15:608.</a></li><li><a class="nounderline abstract_t">Maltais F, Buhl R, Koch A, et al. β-Blockers in COPD: A Cohort Study From the TONADO Research Program. Chest 2018; 153:1315.</a></li><li><a class="nounderline abstract_t">Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:880.</a></li><li><a class="nounderline abstract_t">Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63:301.</a></li><li><a class="nounderline abstract_t">van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178:695.</a></li><li><a class="nounderline abstract_t">Stefan MS, Rothberg MB, Priya A, et al. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012; 67:977.</a></li><li><a class="nounderline abstract_t">Puente-Maestu L, Calle M, Ortega-González A, et al. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med 2014; 108:737.</a></li><li><a class="nounderline abstract_t">Yang YL, Xiang ZJ, Yang JH, et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2020; 41:4415.</a></li><li><a class="nounderline abstract_t">Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med 2019; 381:2304.</a></li><li><a class="nounderline abstract_t">Rasmussen DB, Bodtger U, Lamberts M, et al. Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study. Thorax 2020; 75:928.</a></li><li><a class="nounderline abstract_t">Parekh TM, Helgeson ES, Connett J, et al. Lung Function and the Risk of Exacerbation in the β-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Trial. Ann Am Thorac Soc 2022; 19:1642.</a></li><li><a class="nounderline abstract_t">Au DH, Bryson CL, Fan VS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004; 117:925.</a></li><li><a class="nounderline abstract_t">Benson MK, Berrill WT, Cruickshank JM, Sterling GS. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978; 5:415.</a></li><li><a class="nounderline abstract_t">Fogari R, Zoppi A, Tettamanti F, et al. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990; 4:1145.</a></li><li><a class="nounderline abstract_t">Chazan R. [Atenolol in the treatment of patients with airway obstruction]. Pol Merkur Lekarski 1998; 4:89.</a></li><li><a class="nounderline abstract_t">Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD003566.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97:1094.</a></li><li><a class="nounderline abstract_t">Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.</a></li><li><a class="nounderline abstract_t">van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005; 127:818.</a></li><li><a class="nounderline abstract_t">Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44:497.</a></li><li><a class="nounderline abstract_t">Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55:1780.</a></li><li><a class="nounderline abstract_t">George RB, Manocha K, Burford JG, et al. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest 1983; 83:457.</a></li><li><a class="nounderline abstract_t">Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999; 138:460.</a></li><li><a class="nounderline abstract_t">Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370:2201.</a></li><li><a class="nounderline abstract_t">Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax 2015; 70:33.</a></li><li><a class="nounderline abstract_t">Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 2013; 126:598.</a></li><li><a class="nounderline abstract_t">Saleh HZ, Mohan K, Shaw M, et al. Impact of chronic obstructive pulmonary disease severity on surgical outcomes in patients undergoing non-emergent coronary artery bypass grafting. Eur J Cardiothorac Surg 2012; 42:108.</a></li><li><a class="nounderline abstract_t">Manganas H, Lacasse Y, Bourgeois S, et al. Postoperative outcome after coronary artery bypass grafting in chronic obstructive pulmonary disease. Can Respir J 2007; 14:19.</a></li><li><a class="nounderline abstract_t">Ho CH, Chen YC, Chu CC, et al. Postoperative Complications After Coronary Artery Bypass Grafting in Patients With Chronic Obstructive Pulmonary Disease. Medicine (Baltimore) 2016; 95:e2926.</a></li><li><a class="nounderline abstract_t">de Miguel-Díez J, Jiménez-García R, Hernández-Barrera V, et al. Time trends in coronary revascularization procedures among people with COPD: analysis of the Spanish national hospital discharge data (2001-2011). Int J Chron Obstruct Pulmon Dis 2015; 10:2285.</a></li><li><a class="nounderline abstract_t">Fuster RG, Argudo JA, Albarova OG, et al. Prognostic value of chronic obstructive pulmonary disease in coronary artery bypass grafting. Eur J Cardiothorac Surg 2006; 29:202.</a></li><li><a class="nounderline abstract_t">Medalion B, Katz MG, Cohen AJ, et al. Long-term beneficial effect of coronary artery bypass grafting in patients with COPD. Chest 2004; 125:56.</a></li><li><a class="nounderline abstract_t">Jatene T, Biering-Sørensen T, Nochioka K, et al. Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). Am J Cardiol 2017; 119:14.</a></li></ol></div><div id="topicVersionRevision">Topic 1437 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.goldcopd.org" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20871122" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22959785" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Coronary artery disease is under-diagnosed and under-treated in advanced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23237132" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37653498" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26208998" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29723057" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17311843" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113462" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29442524" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37385658" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36304748" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Nomogram for Predicting Cardiovascular Diseases in Chronic Obstructive Pulmonary Disease Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643237" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20382719" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interactions between COPD and outcomes after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21527507" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23392738" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033321" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22323574" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23024006" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860516" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840745" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665994" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Exercise prescription for hospitalized people with chronic obstructive pulmonary disease and comorbidities: a synthesis of systematic reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979118" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of hypoxaemia on the resting electrocardiogram (ECG) in patients with cardiac ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1642934" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relationship between hypoxaemic and cardiac ischaemic events in the perioperative period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2454781" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872344" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6110912" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6776858" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552015" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Supportive therapy in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783918" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Oxygen therapy and hypoxic drive to breathe: Is there danger in the patient with COPD?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21672999" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25046211" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tiotropium versus placebo for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992515" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tiotropium Respimat inhaler and the risk of death in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511719" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796155" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cardiovascular safety of salmeterol in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596305" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Short-term cardiovascular effects of salmeterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17314337" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20685748" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cardiovascular events in patients with COPD: TORCH study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29297057" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35645559" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796175" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791542" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Are beta2-agonists responsible for increased mortality in heart failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19592475" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cardiovascular safety of tiotropium in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490945" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28185242" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36137586" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972099" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970006" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27203508" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33252985" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32162970" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23412642" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23197074" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21631929" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394145" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2036824" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8970341" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bronchodilators and acute cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639691" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Is the use of beta-blockers in COPD still an unresolved dilemma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29406772" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355547" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : β-Blockers in COPD: A Cohort Study From the TONADO Research Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498416" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17951276" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565952" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22941975" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association betweenβ-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635914" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Multicentric study on the beta-blocker use and relation with exacerbations in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33211823" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association ofβ-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31633896" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Metoprolol for the Prevention of Acute Exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32820080" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363600" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Lung Function and the Risk of Exacerbation in theβ-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15629731" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A comparison of four beta-adrenoceptor antagonists in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1982059" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591440" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : [Atenolol in the treatment of patients with airway obstruction].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235327" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cardioselective beta-blockers for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561016" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12416945" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764762" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358010" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413026" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6337786" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10467196" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836125" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Simvastatin for the prevention of exacerbations in moderate-to-severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349333" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Statin use and exacerbations in individuals with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684060" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Statin use and risk of COPD exacerbation requiring hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290913" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Impact of chronic obstructive pulmonary disease severity on surgical outcomes in patients undergoing non-emergent coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17315054" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Postoperative outcome after coronary artery bypass grafting in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26937939" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Postoperative Complications After Coronary Artery Bypass Grafting in Patients With Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26543361" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Time trends in coronary revascularization procedures among people with COPD: analysis of the Spanish national hospital discharge data (2001-2011).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376093" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prognostic value of chronic obstructive pulmonary disease in coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718421" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Long-term beneficial effect of coronary artery bypass grafting in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27788931" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
